Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases. Prof. Wischik discovered that the neurofibrillary tangles seen in Alzheimer’s disease are made of sub-units of the tau protein and he and his team have published extensively in the field.
Filter by year:All 2021 2020 2019 2018 2017 2016 2015 2014 2012 2011 2010 2009 2008 2007 2006 2005 2001 2000 1998 1997 1996 1995 1994 1993 1992 1991 1990 1988 1986 1985
Bentham, P., et al (2021) Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier. Available at Journal of Alzheimer’s Disease.
Kondak, C., et al (2021) Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine, Available at Journal of Neurochemistry
Maina, M.B., et al (2021) Oxidative stress conditions result in trapping of PHF-core tau (297-391) intermediates. Available at: Cells
Schwab, K., et al (2021) Proteomic Analysis of Hydromethylthionine in the Line 66 Model of Frontotemporal Dementia Demonstrates Actions on
Tau-Dependent and Tau-Independent Networks, Available at Cells
Vuksanovic, V., et al (2021) Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementia, Available at: Brain Communications